# A Study to Test the Safety, Tolerance, and Metabolism of Abacavir (1592U89, ABC) With Standard Zidovudine (ZDV) Therapy in Newborn Infants Born to HIV-1 Infected Women

> **NCT00000864** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 60 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Abacavir sulfate
- **DRUG:** Zidovudine

## Key facts

- **NCT ID:** NCT00000864
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 2001-01
- **Target enrollment:** 60 (—)
- **Last updated:** 2021-10-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00000864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00000864, "A Study to Test the Safety, Tolerance, and Metabolism of Abacavir (1592U89, ABC) With Standard Zidovudine (ZDV) Therapy in Newborn Infants Born to HIV-1 Infected Women". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00000864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*